Stock Ratings / Health Care / EDIT / dividends

PROK (37) ALLO (33) AUTL (21) RGNX (27) ⌘ Pro Terminal →

Editas Medicine Inc. (EDIT) Dividend Safety Gauge & 10-Year DRIP Compounder

$2.67 -8.87% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $2.62

Editas Medicine Inc. (EDIT) carries a Roarable Rating of D- (Sell) with 38/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

📊 Historical Track Record Warning: Scores below 50 (38/100 · D-) historically underperformed SPY in 71% of rolling 90-day windows →

ROARABLE D- • RED ALERT Cap $450.0M

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on EDIT Below — or Connect Your Own ChatGPT / Claude

🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is EDIT stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

▼

As of 2026-11-02, Editas Medicine Inc. (NASDAQ: EDIT) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 38/100 at a spot price of $2.67 (-8.87% 1D, market cap $450.0M). Pillar breakdown: Fundamental Cash Engine 6/20, Institutional 13F & Options Flow 13/20, Executive Insider Alignment 8/20, FRED Macro Regime Fit 8/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, EDIT ranks #578 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief

🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does EDIT compare to PROK and ALLO in the Health Care sector?

▼

Within the Health Care sector (Biotechnology: Biological Products (No Diagnostic Substances)), EDIT carries a Roarable D- (38/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, PROK (ProKidney Corp. (Class A)) holds a D- grade (37/100 RQD, P/E N/A, ROIC -35.0%, cap $444.4M) and ALLO (Allogene Therapeutics Inc.) posts a E grade (33/100 RQD, P/E N/A, ROIC -35.0%, cap $431.9M). Among the 5-stock peer group, EDIT leads on earnings multiple (N/A) while EDIT leads on capital efficiency (-35.0% ROIC).

✓ Pre-computed one-to-many AI Quant brief

🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for EDIT?

▼

Per EDIT's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001650664), Editas Medicine Inc. generated $40.5M in revenue (+25.4% YoY), -$160.1M in net income, and -$165.8M in free cash flow against $186.5M in total assets and $53.6M in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief

🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $2.62 (-1.79%)🧬 Dilution Drag (+1.28% YoY Shares)⚙️ Cash Engine: 6/20 (E) • 0% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record Warning: Scores below 50 (38/100 · D-) historically underperformed SPY in 71% of rolling 90-day windows (-7.8% avg 90D alpha vs SPY • 29.0% hit rate).

Audit Bucket Track Record →

RQD QUANT TACHOMETERRED ALERT • D-

3-of-3 JEV AI Jury Bearish Warning

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw D- · Rk D-

Each axis scored 0–20

12M PRICE TARGET CONE-9% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for EDIT)Realized 20D OHLCV Swing Band: ±12.5%

Deterministic 5-Pillar Attribution (38/100 Composite)

🔍 WHY EDIT SCORES 38/100 (D-) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: Whale & Options Positioning+13/20 pts (34% of score)

20D Institutional Volume Accumulation (±12.5% realized swing band)

▲ #2 Bullish Driver: SEC 10-K Forensic Risk+8/20 pts (21% of score)

Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 3/9

▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution4/20 pts (-16 pt drag)

Dilution Drag (+1.28% YoY Shares) & executive Form 4 sales trim 16 pts from alignment

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade D$2.75-12% Next Q

Q2 (-2Q)

Grade D$2.42-0.8% Next Q

Q3 (-1Q)

Grade D$2.40+11.3% Next Q

Current

Grade D-$2.67-7.8% Hist 90D α

Trajectory: D (46) → D- (38)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a EDIT Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While EDIT currently carries a cautious 38/100 (D-) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($2.76) and Max Pain ($2.80) forces dealer call-delta covering toward $4.14.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Dilution Drag (+1.28% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $EDIT• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “EDIT Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”

YES 38%NO 62%Trade / Inspect Odds →

CASH DIVIDEND + BUYBACK YIELD

1.8% Total Yield

0% Cash ($0.00/yr) + 1.8% Buybacks

PAYOUT SAFETY SPEEDOMETER

74/100 • REINVESTING IN GROWTH + BUYBACKS

FREE CASH FLOW PAYOUT RATIO

0% (100% Reinvested)

Retains cash flow for R&D and share repurchases

INTERACTIVE DRIP & SHAREHOLDER-YIELD COMPOUNDER (15.8% EST. ANNUAL)

$10,000 Compounded Over 10 Years → $43,360

Est. Year-10 Shareholder Yield: $780/yr

Starting Investment: $10,000

Compounding Horizon: 10 Years

$11.6K

Yr 1

$13.4K

Yr 2

$15.5K

Yr 3

$18.0K

Yr 4

$20.8K

Yr 5

$24.1K

Yr 6

$27.9K

Yr 7

$32.3K

Yr 8

$37.4K

Yr 9

$43.4K

Yr 10

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring EDIT)

✓Walkthrough of EDIT's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

EDIT // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -11.00%▼ DESCENDING CHANNEL

2026-11-02O $2.95H $2.95L $2.67C $2.67VOL 3.23M

RES: $2.96SUP: $2.09SMA50: $2.76SMA200: $2.69

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

EDIT Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 EDIT Butterfly Map → + Track EDIT →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

8.0%/yr Implied 5Y Growth

vs. +25.4% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on EDIT today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for EDIT. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for EDIT today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (EDIT)

Health Care Rank #578 of 1016 ⚔️ PROK vs EDIT Full Matrix →

1. Head-to-Head Health Care Peer Comparison (EDIT vs. PROK, ALLO, AUTL, RGNX)

Industry: Biotechnology: Biological Products (No Diagnostic Substances) (156 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Editas Medicine Inc. (EDIT) ranks #578 by composite RQD confidence (38/100, grade D-) and #466 by equity capitalization ($450.0M). Within this direct 5-issuer industry benchmark cohort, EDIT leads on earnings valuation at N/A trailing P/E, while EDIT leads on capital efficiency and profitability with -35.0% ROIC and — gross margin. EDIT currently leads its immediate peer cohort in composite quantitative strength at 38/100 (D-).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
EDIT ACTIVE Editas Medicine Inc.	D-	38/100	—	—	-35.0%	-8.87%	$450.0M	Benchmark Subject
PROK ProKidney Corp. (Class A)	D-	37/100	—	—	-35.0%	-11.90%	$444.4M	/prok-vs-edit →
ALLO Allogene Therapeutics Inc.	E	33/100	—	—	-35.0%	-5.60%	$431.9M	/allo-vs-edit →
AUTL Autolus Therapeutics plc	E	21/100	—	-27.8%	-35.0%	-3.80%	$420.5M	/autl-vs-edit →
RGNX REGENXBIO Inc.	E	27/100	—	—	-35.0%	-2.83%	$489.2M	/rgnx-vs-edit →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001650664

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Editas Medicine Inc. (EDIT) reported GAAP revenue of $40.5M (+25.4% vs. FY2024 revenue of $32.3M , and -48.1% cumulative change since FY2023) , GAAP net income of -$160.1M, operating cash flow of -$165.2M, and free cash flow of -$165.8M (+24.3% YoY). On the balance sheet, EDIT closed FY2025 with $186.5M in total assets against $53.6M in total debt (Altman Z-Score: N/A, Piotroski F-Score: 3/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$40.5M	-$160.1M	-$165.2M	-$165.8M	$186.5M	$53.6M
FY2024 (FY)	2024-12-31	$32.3M	-$237.1M	-$210.3M	-$219.1M	$341.6M	$52.4M
FY2023 (FY)	2023-12-31	$78.1M	-$153.2M	-$132.2M	-$132.2M	—	—

3. EDIT Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is EDIT stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

How does EDIT compare to PROK and ALLO in the Health Care sector?

What are the biggest fundamental strengths and SEC risk factors for EDIT?

Where is EDIT trading relative to its 50-day, 200-day, and 52-week technical levels?

EDIT last traded at $2.67 (-8.87% on volume of 2,909,260 shares), positioning the stock -3.26% below its 50-day simple moving average ($2.76) and -0.74% below its 200-day simple moving average ($2.69). Across its 52-week range of $1.66 to $3.94, EDIT sits at the 44.3% percentile with a 14-day RSI of 57.6 (BULLISH MOMENTUM) and an implied next-earnings move of ±12.5% ($2.34 to $3.00).

EDIT Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

Does EDIT pay a dividend and is it safe?

Editas Medicine Inc. (EDIT) offers a 0% cash dividend yield ($0.00 annualized) and 1.8% total shareholder yield including buybacks. Roarable rates its payout coverage as REINVESTING IN GROWTH + BUYBACKS.

Direct Sub-Reports: EDIT RQD Cockpit EDIT 12M Forecast EDIT Earnings & Move EDIT Dividends & DRIP EDIT Insiders & 13F EDIT Whale Options EDIT Profit Sankey EDIT News & Why

ROARABLE RATING BRIEF • RQD 38/100 (D-) ✓ STAGE-C NUMBER FIREWALL VERIFIED

EDIT — Editas Medicine Inc.: What the Facts Mean to a Prospective Investor

Engine: anthropic/claude-haiku-5.5

As of: 2026-11-02T15:36:20Z

Roarable Rating Brief: What This Means to a Prospective Investor

Per the Roarable RQD rating, EDIT carries an RQD Score of 38 out of 100, a letter grade of D-, and the verdict label "Roarable Sell — Vulnerable Balance Sheet & Flow." Across the five pillars:

Fundamental Cash Engine (6 / 20): Per the Roarable RQD rating, ROIC is -35% and FCF yield is 0%. For a prospective investor, this pillar is the weakest signal: the business is not currently generating returns on capital or free cash flow that would support valuation on cash-earnings grounds, so any upside case depends on future value creation rather than present cash generation.
Whale / 13F Flow (13 / 20): Per the Roarable RQD rating, this pillar reflects institutional accumulation and options positioning. It is the strongest pillar in the set, indicating some institutional interest, though the underlying holder detail is not available in the source data.
Insider Conviction (3 / 20): Per the Roarable RQD rating, this pillar reflects SEC Form 4 and Congressional PTR cluster flow and scores low. For a prospective investor, weak insider conviction is a caution flag rather than a definitive negative, since the specific trade detail is not provided.
Macro Regime Fit (8 / 20): Per the Roarable RQD rating, beta is 1.0 with sector sensitivity noted. The stock moves in line with the broader market, offering no defensive cushion, and its exposure to sector-level sentiment is a source of volatility.
Forensic Balance Sheet (8 / 20): Per the Roarable RQD rating, Altman Z is 2.5, Piotroski F is 3/9, and Debt/Equity is 1.96. The Piotroski score is weak and leverage relative to equity is elevated, which constrains financial flexibility.

Taken together, the score points to valuation tradeoffs: the equity is priced in the context of persistent operating losses, and the upside case rests on pipeline or strategic outcomes that the source data does not quantify. The downside risks are balance-sheet and cash-burn driven.

Business

Editas Medicine Inc. (EDIT) is a NASDAQ-listed issuer in the Health Care sector, operating in the Biotechnology: Biological Products (No Diagnostic Substances) industry. Per the company profile, the company has a market capitalization of $0.4B. The source data does not describe its products, customers, or revenue model in detail beyond the financial figures and news headlines.

Financial Trend

Period	Revenue	Operating Income	Net Income	EPS	FCF	Cash	Debt
FY 2025	$40.5M	$-160.0M	$-160.1M	N/A	$-165.8M	$146.6M	$53.6M
FY 2024	$32.3M	$-251.2M	$-237.1M	N/A	$-219.1M	$131.5M	$52.4M
FY 2023	$78.1M	$-169.2M	$-153.2M	N/A	$-132.2M	N/A	N/A

Per the SEC financials, the company reported operating losses and negative free cash flow across all three periods. Per the market data, the gross margin is 0%, the operating margin is -60%, and the net margin is -60%. Per the Roarable RQD rating, ROIC is -35% and the Altman Z-Score is 2.5, with a Piotroski F-Score of 3/9 and a Debt/Equity ratio of 1.96. Per the SEC financials, cash was $146.6M against debt of $53.6M at FY 2025, a larger cash balance than debt, though cash burn in FY 2025 exceeded the reported cash balance's annual change.

Recent Catalysts & News Wire Analysis

Clearance of EDIT-401 trial (YELLOW, Market Wire): A headline reports shares rising after Australia cleared a Phase 1/2 trial of EDIT-401.
Downgrade on reni-cel discontinuation (RED, Risk Watch): A Seeking Alpha item reports a downgrade to 'Hold' tied to the discontinuation of reni-cel for SCD/TDT and a strategic shift toward EDIT-401.
Preclinical cholesterol data (YELLOW, Market Wire): A Stock Titan item reports an experimental gene-editing drug kept monkeys' bad cholesterol about 90% lower for 10 months.
Consensus target (YELLOW, Market Wire): A MarketBeat item reports a consensus price target of $5.80.
Estimates and market coverage (YELLOW, Market Wire): Yahoo Finance Singapore and TradingView items cover general market action and estimates.

Per the Butterfly Supply-Chain Graph, the supply chain is listed as NONE, with no butterfly links and no proprietary signals.

Analyst View & Smart Money Ownership

Per the analyst data, no analyst records are available. Per the holders section, no holder records are available. The consensus price target of $5.80 is referenced only in the news wire headline above, not in an analyst data record. No SEC Form 4, 13F, or Congressional trade detail is provided in the source data beyond the RQD pillar scores.

Open Questions

What are the specific product and revenue sources that generated the FY 2025 revenue of $40.5M?
What is the timeline and cash runway implied by the FY 2025 cash balance of $146.6M against the FY 2025 free cash flow of $-165.8M?
What insider and institutional trades underlie the insider (3 / 20) and whale-flow (13 / 20) pillar scores?
What is the status and risk profile of the EDIT-401 program following the reported strategic shift?
What is the basis for the reported consensus price target of $5.80, and which analysts contribute to it?

EDIT Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Editas Medicine Inc. (EDIT) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to EDIT Debate Forum (3) ↓

🟡 MARKET WIRE Yahoo Finance Singapore • 13h ago

Editas Medicine, Inc. (EDIT) stock price, news, quote and history

Yahoo Finance Singapore report covering Editas Medicine Inc. (EDIT) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE TradingView • 16h ago

Editas Medicine, Inc. Estimates – NASDAQ:EDIT

TradingView report covering Editas Medicine Inc. (EDIT) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🔴 RISK WATCH Seeking Alpha • 19h ago

Editas: Downgrade To 'Hold' On Reni-Cel Discontinuation SCD/TDT And EDIT-401 Strategic Shift

Seeking Alpha report covering Editas Medicine Inc. (EDIT) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE MarketBeat • 22h ago

Editas Medicine, Inc. (NASDAQ:EDIT) Stock Has Consensus Price Target of $5.80 According to Analysts

MarketBeat report covering Editas Medicine Inc. (EDIT) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Stock Titan • 1d ago

An experimental gene-editing drug kept monkeys' bad cholesterol about 90% lower for 10 months

Stock Titan report covering Editas Medicine Inc. (EDIT) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Yahoo Finance • 1d ago

Update: Editas Medicine Shares Rise After Australia Clears Phase 1/2 Trial of EDIT-401

Yahoo Finance report covering Editas Medicine Inc. (EDIT) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Simply Wall St • 1d ago

Editas Medicine (NasdaqGS:EDIT) Stock Forecast & Analyst Predictions

Simply Wall St report covering Editas Medicine Inc. (EDIT) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Seeking Alpha • 1d ago

Editas wins Australia nod for gene editing trial (EDIT:NASDAQ)

Seeking Alpha report covering Editas Medicine Inc. (EDIT) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

EDIT Bull vs. Bear Conversation Board — What's Your Call at $2.67?

🐂 33% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON EDIT 🐻 67% BEARISH CONVICTION

RO RoarDesk_Moderator Roarable Research Desk 🐻 BEARISH 🎯 Target: $2.58 (-11.9%)

📌 Pinned Debate

🔥 Official Bull vs. Bear Debate: Is EDIT (D- • RQD 38/100) a Buy at $2.93?

Welcome to the EDIT (Editas Medicine Inc.) Roar Pit. Current RQD Composite is 38/100 (Roarable Sell — Vulnerable Balance Sheet & Flow) in Biotechnology: Biological Products (No Diagnostic Substances). Bulls point to operating leverage and sector positioning, while bears focus on macro rate sensitivity and margin execution. Pick your side (🐂 Bull or 🐻 Bear) and drop your price target below.

RI RiskArb_Desk Forensic Accounting Watch 🐻 BEARISH 🎯 Target: $2.20 (-24.9%)

Spot @ $2.93

Pump the brakes on EDIT — check the valuation vs. margin headwinds

Everyone in here is repeating the bull case on EDIT, but look at what you are paying: current EV/EBITDA multiples with tightening sector spreads. Unless Editas Medicine Inc. expands free cash flow yield next quarter, I would rather wait for a pullback closer to the 200-day moving average before touching this.

DE DeltaGamma_99 Verified K Arena Trader 🐂 BULLISH 🎯 Target: $3.46 (+18.1%)

Spot @ $2.93

EDIT cash flow & RQD setup is being underpriced by the Street here

Looking at the 5-pillar RQD breakdown on EDIT, the market is fixating on short-term headline noise in Biotechnology: Biological Products (No Diagnostic Substances) and ignoring the balance sheet and cash flow trajectory. At $2.93 (52-wk range $1.66 - $3.94), any beat on forward guidance forces shorts and underweight funds to chase.